Drugs cost too much. There is a better way to fund medical innovation

Drugs Medicine 2018 United Nations

UNICEF/Olivier Asselin In Côte d’Ivoire, a counsellor from UNICEF partner NGO Femme Active, instructs an adolescent boy, diagnosed with HIV in 2012, on how to take his antiretroviral (ARV) medication correctly.

This article is brought to you based on the strategic cooperation of The European Sting with the World Economic Forum.

Author: Rufus Pollock, Lead, iMed Project, and Founder and President of Open Knowledge

Drugs are expensive. Very expensive, and becoming ever more so, it seems. Prices for new medicines have been steadily rising for the past few decades. It costs a great deal to bring new drugs to market, the explanation goes, and without high prices, the pipeline of new medicines will run dry.

This argument is unsustainable, especially when even the world’s most developed economies and healthcare systems are struggling to afford vital medicines. To keep paying more for drugs simply cannot be the answer. Bad health affects everyone. We should be urgently seeking new mechanisms of funding medical innovation that do not compromise on access.

There is a strong moral and social obligation for exploring alternatives. Millions of people globally do not have access to the medicines they need to survive. In the US, millions of adults skip prescribed medications due to the high cost. The same is true in Canada, where the public healthcare system does not usually extend to cover prescription medicines, and in Europe, especially in poorer members of the EU.

The situation is worse in less developed countries. Many pay out of pocket for drugs, and the hefty price tags can run many times the annual average income. Two widely used drugs for treating hepatitis C cost the equivalent of one or more years’ average earnings in 12 out of 30 countries, revealed a recent study by the World Health Organization. Millions are dying because they cannot afford the medicine they need to stay alive.

When some members of society lack medicine, there are consequences beyond the individual directly affected. The increased morbidity caused by a lack of access to medication places an extraordinary strain on healthcare systems, exacerbating the drain on their resources from ever more expensive drugs. In addition, unhealthy populations are far less economically productive than healthy ones. Beyond social justice, there are clear economic reasons to find new models of funding medical innovation that do not restrict access to medicine.

The current state of affairs is making the world a more dangerous place. Healthcare systems that are strained by increased morbidity, and by a critical lack of money and medicine, are less likely to be able to contain outbreaks when they occur. Poor global health increases global instability. Failing to ensure everyone has access to necessary medication can have profound knock-on consequences and worsen existing crises.

Moreover, the high sale price of drugs skews incentives for innovation towards wealthy consumers. This means that vital medicines for certain ailments are not accessible when needed on a global scale. For instance, the Ebola virus had been known about for decades before the recent outbreak, and yet virtually no treatments were available. The whole world is unprepared and at risk.

The explanation that pharmaceutical companies offer for high drug prices is compelling. It costs a great deal of money to bring a drug to market, they argue. This is why so many reluctantly accept the current state of affairs, in which innovation justifies restricted access. Though it is true that drugs do cost a lot to bring to market, there is a remarkable lack of consensus on exactly how much.

This is compounded by a systemic lack of transparency. It is often not known how much is spent on what, and how reliant private-sector developments are on publicly funded research. Often, medicines that are developed with significant help from public funds do not reflect that support in prices, and there is no guarantee under the monopoly rights patent system that they should.

Moreover, a great deal of money that could be earmarked for research is spent on marketing instead. Indeed, in some large drug companies, expenditure on marketing outweighs that on research.

This model is unsustainable. So long as we continue to reward innovation through a single channel – buying the drug – access to new medicines will be limited. Ultimately, the problem is about how we pay for medicine. Today, we only pay by purchasing the end product. This means that the costs of manufacture (which is cheap) and innovation (which is expensive) are rolled into one. This puts access and innovation in conflict.

If we were to change how we fund medicines, there could be no conflict. Incentives for innovation and access to affordable drugs could co-exist. We can fund research and production separately. There is no excuse for not exploring the wide systemic changes needed to make that happen.

Today’s model is unsustainable, unhealthy and utterly unnecessary. We can have new medicines and wide access to them. We should be working towards this as a matter of urgency.

And we have ideas. For example, at the iMed Project we’ve been developing innovative two-part payment models for funding medicines that would maintain incentives for innovators while making treatment at cost of manufacture.”

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

the European Sting Milestones

Featured Stings

Stopping antimicrobial resistance would cost just USD 2 per person a year

HPV vaccine: the silver bullet that saves women

Is there a chance for the West to win the war on terror?

Five years down the drain

4 things to know about the state of conflict today

Europe again the black sheep at the G20 Finance Ministers and Central Bank Governors

Towards a tobacco free India

Climate change: Direct and indirect impacts on health

MWC 2016 LIVE: Xiaomi looks to revive growth with flagships

Why Eurozone’s problems may end in a few months

Work Together to Build a New Type of International Relations and a Community with a Shared Future for Humanity

Greece to stay in the euro area but the cost to its people remains elusive

Who will secure Lithuania?

5 technologies that will forever change global trade

To hope or doubt? The state of women’s progress in the world

UN, Somali Government seek $80 million in immediate relief for flood-affected populations

How do we build an ethical framework for the Fourth Industrial Revolution?

An American duel in Brussels: Salesforce against Microsoft over Linkedin deal

Guinea President Alpha Condé: “We must tackle the root causes of migration”

VW emissions scandal: While U.S. car owners are vindicated, Europe still unable to change its laws and protect its consumers

A new catastrophic phase in the Syrian carnage

‘Two pack’ austerity package in force but with less vigor

Eurozone and Britain heading in different directions

This is what countries are doing to fight plastic waste

5 ways to net a sustainable future for aquaculture

COP21 Breaking News_10 December:#ParisAgreement: Points that remain in suspense

DiscoverEU: 15,000 travel passes up for grabs to explore the EU this summer

European Fund for Transition to support more workers made redundant

A day in the life of a refugee: the role of nations and citizens of the world

Jade Spring Meeting 2017 – day 2: Coporate workshops, general assembly and magna moment

How can we build a workforce for our digital future?

“Leaked” TTIP document breaks post 8th negotiations round silence and opens door to critics

New UN agriculture agency report underscores value of fishing in fight against global hunger

Service and Sacrifice: For Ghana, UN peacekeeping is a ‘noble opportunity to serve humanity’

The UN supports Europe’s military action in Libya and the Mediterranean; Russia and China agree

Achieving targets on energy helps meet other Global Goals, UN forum told

The Changing Scope of International Economic Relations – Chinese Leadership in the 21st Century

EU to present a “hefty” exit bill to the UK moments before Brexit negotiations

A Sting Exclusive: Towards better business opportunities for the EU and its neighbours, Commissioner Hahn live from European Business Summit 2015

These clothes grow with your child

UN’s AIDS agency ‘greatly encouraged’ by latest scientific breakthrough showing cure is possible

Counting spillovers from the fast track EU-US free trade agreement

What the car industry has done to help fight climate change – and what it needs to do next

What data dominance really means, and how countries can compete

Gig economy: Employment Committee MEPs want to boost workers’ rights

‘Crimes against humanity,’ ‘war crimes’ and risk of new ethnic violence in DR Congo, warn UN experts

Everything you need to know about the US government shutdown

The world’s e-waste is a huge problem. It’s also a golden opportunity

Trump’s blasting win causes uncertainty and turbulence to the global financial markets

French elections: by the time the EU economy revives and the migration crisis is solved extremists could take over Europe

South Sudan: UN condemns ‘brutal’ sexual assaults on roads to Bentiu

Project Manager – 2024

EU-US resume trade negotiations under the spell of NSA surveillance

Italian Prime Minister Giuseppe Conte: “Europe must listen to the people”

These coastal countries are sinking the fastest

European Union: From financial consolidation to deeper political division

Volkswagen scandal update: “We want clarity fast, but it is equally important to have the complete picture”, Commission’s spokesperson underscores from Brussels

What the global Internet’s stakeholders can learn from Europe’s new data law

Parliament backs a modernised EU electoral law

Women in Iceland have walked out of work to dispute the gender pay gap

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s